Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.56|
|52 Week High||US$9.98|
|52 Week Low||US$23.04|
|1 Month Change||3.03%|
|3 Month Change||-14.94%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-28.20%|
Recent News & Updates
Is Tilray Stock Overvalued Or Undervalued? Still Overvalued Now, But Looking Cheap Enough
TLRY stock has now pulled back some 85% from early-year, bubbly highs. Shares aren't necessarily 'cheap' at this level, but valuation has come in. The longer-term strategy seems wise, and Tilray's reach and production capacity strongly suggest it can survive until the U.S. market finally opens up. The answer to a simple question suggests that TLRY has become one of the more attractive cannabis plays out there.
Tilray, Inc. (NASDAQ:TLRY) May be Risky for Institutions but Good for Traders
Tilray, Inc. (NASDAQ:TLRY), is far from the trading high at US$29 in February 2021 as the stock is currently searching for a bottom. The company has a gap in performance and a wide area of possible outcomes. The last earnings report has re-motivated some investors, and perhaps the company will indeed show meaningful growth, but until then, we will look at what the shareholder composition says about the company.
Tilray: Out Of Touch
Tilray reported another quarter consistent with the constant earnings misses of Canadian cannabis stocks. The company only reported minimal pro-forma growth above the FQ1'21 revenues of $165 million. The stock trades at nearly 10x FY22 sales targets, ex-distribution revenues, providing limited upside potential and substantial downside risk, if targets aren't met.
Tilray: 250 Million Reasons Shareholders Aren't Happy
Tilray continues to urge shareholders to approve Proposal 1 to lift the authorized share count to 990 million shares. The Canadian cannabis company has proposed a plan to boost FY24 (June) revenue to $4 billion while current analyst estimates are only $1.37 billion. Investors are rightfully balking at the company boosting the authorized shares by ~250 million when organic growth is preferred.
Estimating the Intrinsic Value of Tilray, Inc. (NASDAQ:TLRY)
While cannabis remains one of the prominent growth stories, Tilray (NASDAQ:TLRY) is having one of the more peaceful periods in the history of this extremely volatile stock. Yet, after the latest declines, the stock could not make a fresh low, showing a sign of potential bottoming. In this article, we will examine the latest developments and examine the current intrinsic value based on the discounted cash flow (DCF) valuation model.
|TLRY||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how TLRY performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TLRY performed against the US Market.
Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: Insufficient data to determine TLRY's volatility change over the past year.
About the Company
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products.
Tilray Fundamentals Summary
|TLRY fundamental statistics|
Is TLRY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TLRY income statement (TTM)|
|Cost of Revenue||US$424.43m|
Last Reported Earnings
Aug 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.81|
|Net Profit Margin||-66.49%|
How did TLRY perform over the long term?See historical performance and comparison
Is Tilray undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TLRY ($11.56) is trading below our estimate of fair value ($13.31)
Significantly Below Fair Value: TLRY is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TLRY is good value based on its PB Ratio (1.2x) compared to the US Pharmaceuticals industry average (3.1x).
How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: TLRY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TLRY's is expected to become profitable in the next 3 years.
Revenue vs Market: TLRY's revenue (22% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: TLRY's revenue (22% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TLRY's Return on Equity is forecast to be low in 3 years time (1.3%).
How has Tilray performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TLRY is currently unprofitable.
Growing Profit Margin: TLRY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 78.2% per year.
Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: TLRY has a negative Return on Equity (-7.95%), as it is currently unprofitable.
How is Tilray's financial position?
Financial Position Analysis
Short Term Liabilities: TLRY's short term assets ($844.6M) exceed its short term liabilities ($526.8M).
Long Term Liabilities: TLRY's short term assets ($844.6M) do not cover its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: TLRY's debt to equity ratio (18.6%) is considered satisfactory.
Reducing Debt: TLRY's debt to equity ratio has increased from 10.6% to 18.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TLRY has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Tilray current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Irwin Simon (63 yo)
Mr. Irwin David Simon has been Chairman of the Board of Tilray, Inc. since December 27, 2018, Chief Executive Officer since March 1, 2019 and President since May 4, 2021. Mr. Simon has been Executive Chair...
CEO Compensation Analysis
Compensation vs Market: Irwin's total compensation ($USD13.68M) is above average for companies of similar size in the US market ($USD6.29M).
Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.
Experienced Management: TLRY's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: TLRY's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 60.1%.
Tilray, Inc.'s employee growth, exchange listings and data sources
- Name: Tilray, Inc.
- Ticker: TLRY
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.356b
- Shares outstanding: 463.34m
- Website: https://www.tilray.com
Number of Employees
- Tilray, Inc.
- 655 Madison Avenue
- Suite 1900
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 23:06|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.